Anika Nonnenmacher - Concepedia

Author

Anika Nonnenmacher

Charité - Universitätsmedizin Berlin

Also Known As

Anika Nonnenmacher

Publications

501

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin Freie Universität Berlin German Cancer Research Center Heidelberg University Humboldt-Universität zu Berlin

About

Anika Nonnenmacher is an author at Charité - Universitätsmedizin Berlin specializing in medicine, tumor microenvironment, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	189
2	Cell Biology	3	3	96
3	Immunology	2	2	76
4	Engineering	1	1	13
5	Nephrology	1	1	16

Anika Nonnenmacher

Publications

490

Citations

H-Index

Page 1

	Year	Citations
Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients Zhian Liu, Alberto Fusi, Eva Klopocki, Journal of Translational Medicine	2011	184
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma Antonia Busse, Anne Marie Asemissen, Anika Nonnenmacher, European Journal of Cancer UrologyImmunomodulatory EffectsCancer ImmunosurveillanceGenitourinary CancerImmunology	2011	60
Detection of mutations in circulating cell‐free DNA in relation to disease stage in colorectal cancer Sandra Liebs, Ulrich Keilholz, Inge Kehler, Cancer Medicine	2019	48
Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway Annett Niemetz-Rahn, Anika Nonnenmacher, Johannes Tucholski, Targeted Oncology Cutaneous BiologyMelanomaEgfr PathwayWound HealingDermatology	2014	43
Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells? Antonia Busse, Anne Letsch, Alberto Fusi, Clinical & Experimental Metastasis Cancer ImmunosurveillanceTumor TargetingCell BiologySmall SpheresSuitable Targets	2013	40
PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab‐docetaxel Katharina Pfisterer, Alberto Fusi, Konrad Klinghammer, Head & Neck	2014	25
Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients Anastasia Dielmann, Anne Letsch, Anika Nonnenmacher, Cancer Immunology Immunotherapy UrologyGenitourinary CancerKidney ResearchMedicineFavorable Prognostic Influence	2016	17
Systemic Immune Tuning in Renal Cell Carcinoma Antonia Busse, Anne-Marie Asemissen, Anika Nonnenmacher, Journal of Immunotherapy Sorafenib TreatmentRenal PathologyImmunologyRenal InflammationImmunoediting	2010	16
B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720 Aline I. Riechardt, Anna-Karina B. Maier, Anika Nonnenmacher, British Journal of Ophthalmology	2015	15
Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination Antonia Busse, Anne Letsch, Carmen Scheibenbogen, Journal of Translational Medicine	2010	15

Page 1